EU fines six for pay-for-delay
The European Union is fining drugmakers over efforts to keep generics of the blood-pressure drug perindopril off the market.
Bloomberg reports that the EU has fined six drugmakers, including brand owner Les Laboratories Servier ($451 million) and generic maker Teva ($21 million), over the pay-for-delay strategy which extended the brand's hold on the marketplace.
Bloomberg says the EU's accusations against Servier included making agreements with generics makers to keep generics out of pharmacies and acquiring competing technologies.
Krka Group, Mylan Laboratories, Unichem Laboratories and Lupin Ltd., were also fined.